Theriva Biologics, Inc. (TOVX) Earnings Signals & AI Vibe Check

Latest Filing: 10-K  |  Filed Dec 03, 2026

Cross-checked across multiple AI analysts and grounded in the latest SEC filing.

powered by: earningsVibe.ai

Question:
What is the latest filing signal for Theriva Biologics, Inc.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest 10-K, Theriva Biologics, Inc.'s filing signal turned negative.
earningsVibe SuperAnalyst™ Verdict: TURNED NEGATIVE

Signal Performance — Stock Price Since Filing

30-Day Change
+28.17%
from filing date
60-Day Change
Pending
from filing date

Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT

PERPLEXITY
Continuing Negative
GEMINI
Turned Positive
CLAUDE
Turned Negative
CHATGPT
Continuing Negative

Unlock the Full Filing Analysis

See full earningsSig™ and risksSig™ analysis across 5,000+ companies

Get Started Free →

No credit card required

Question:
What does Theriva Biologics, Inc. actually do?
Answer:
Theriva Biologics, Inc. is a clinical-stage biopharmaceutical company focused on developing oncolytic virus (OV) therapies for cancer. Its lead product candidate, VCN-01, is an oncolytic adenovirus engineered for intravenous delivery, designed to selectively replicate in tumor cells and degrade the tumor stroma to enhance therapeutic penetration. VCN-01 is being evaluated in clinical trials for pancreatic cancer and retinoblastoma, with prior research in gastrointestinal diseases. The company is also developing next-generation OVs under its VCN-X program. Theriva Biologics operates primarily in the United States and Spain, relying on third-party contract manufacturing organizations for its product candidates.
Question:
What are Theriva Biologics, Inc.'s revenue drivers?
Answer:
The company currently has no products approved for commercial sale and does not expect to generate revenue in the near future. Future revenue is contingent on the successful development, regulatory approval, and commercialization of its product candidates, primarily VCN-01.

Cut through noisy SEC filings to find the signal faster

Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.

Get Started Free →

No credit card required